Toxicology International
DOI: 10.18311/ti/2026/v33i3/50592
INFORMATICS JOURNALS
eISSN: 0976-5131 | Vol 33(3), 2026 | pp. 527-544

Impact of Pharmaceutical Care Interventions on Clinical Outcomes in Type II Diabetes Mellitus: Current Evidence, Challenges, and Future Perspectives

G. Susmitha[1*] and R. Gandhimathi[2]

[1]*Department of Pharmacy Practice, VISTAS, Chennai – 600117, Tamil Nadu, India; susmi.aswi@gmail.com*

[2]*Department of Pharmaceutical Chemistry, VISTAS, Chennai – 600117, Tamil Nadu, India*

Abstract

Type II Diabetes Mellitus (T2DM) is a rapidly growing global health concern associated with significant morbidity, mortality, and economic burden. Despite advances in pharmacotherapy, achieving optimal glycemic control remains a major challenge due to poor adherence, complex treatment regimens, and fragmented healthcare delivery. Pharmaceutical care, a patient-centred approach led by pharmacists, has emerged as an effective strategy to improve diabetes management outcomes. This review critically evaluates evidence from interventional studies demonstrating the impact of pharmacist-led services, including medication therapy management (MTM), patient counselling, lifestyle modification support, and continuous monitoring. These interventions have been consistently associated with significant reductions in HbA1c (0.5–2%), improved medication adherence, enhanced quality of life, and decreased hospitalisation rates. The review further explores the integration of emerging technologies such as mobile health (mHealth), telepharmacy, clinical decision support systems (CDSS), and artificial intelligence (AI) in optimising pharmaceutical care delivery. Key barriers, including healthcare system limitations, lack of reimbursement policies, and interdisciplinary coordination challenges, are also discussed.

Major Findings: Pharmaceutical care significantly improves clinical, humanistic, and economic outcomes in T2DM. Integrating pharmacists into multidisciplinary healthcare teams and leveraging digital innovations offers a scalable and effective approach to enhancing long-term diabetes management and reducing disease burden.

Keywords: Adherence, Artificial Intelligence, Medication Therapy Management, Pharmaceutical Care, Type II Diabetes Mellitus

1. Introduction

1.1 Global Burden and Trends of Type II Diabetes Mellitus (T2DM)

Type II Diabetes Mellitus (T2DM) has emerged as one of the most critical global health challenges of the 21st century, reflecting profound shifts in lifestyle, nutrition, and demography. According to the International Diabetes Federation (IDF) Diabetes Atlas (10th edition), approximately 537 million adults aged 20–79 years were living with diabetes in 2021, and this number is projected to escalate to 643 million by 2030 and 783 million by 2045. T2DM accounts for nearly 90% of these cases, highlighting its dominant role in the diabetes epidemic. The prevalence of T2DM has almost quadrupled since 1980, fuelled largely by rising rates of obesity, sedentary behaviours, urbanisation, and increased life expectancy. While the burden of T2DM is global, it disproportionately affects low- and middle-income countries (LMICs), where nearly 80% of cases now reside. In these regions, rapid urbanisation and nutrition transitions have dramatically altered dietary habits and physical activity patterns, contributing to higher rates of obesity and metabolic

Article Received on: 12.07.2025 **Revised on:** 13.05.2026. **Accepted on:** 18.05.2026

**Author for correspondence*

disorders. Simultaneously, healthcare infrastructure in many LMICs struggles to keep pace with the rising incidence, leading to late diagnoses and suboptimal disease management. This global distribution underscores not only the scale of the epidemic but also the critical importance of health system adaptation to local needs[1].

Beyond its rising prevalence, T2DM exerts a heavy toll through its complications. Chronic hyperglycemia leads to microvascular complications—including diabetic retinopathy, nephropathy, and neuropathy—as well as macrovascular complications such as coronary artery disease, stroke, and peripheral arterial disease. Collectively, these complications significantly increase morbidity, mortality, and healthcare costs. According to the IDF, global health expenditures related to diabetes reached approximately USD 966 billion in 2021, representing an increase of over 300% in the past 15 years. As populations age and obesity rates climb, these costs are expected to grow even further, threatening the sustainability of health systems worldwide[2]. Despite extensive research on diabetes management, existing literature often evaluates pharmaceutical care interventions in isolation, without integrating recent technological advancements or future-oriented strategies such as artificial intelligence and pharmacogenomics. Furthermore, there is limited synthesis of evidence linking clinical outcomes with economic and humanistic benefits within a unified framework.

The novelty of this review lies in its comprehensive integration of pharmacist-led interventions with emerging digital health technologies and personalised medicine approaches. By bridging clinical evidence, implementation challenges, and future innovations, this review aims to provide a holistic perspective on optimising pharmaceutical care in T2DM.

Therefore, the objective of this study is to critically analyse the impact of pharmaceutical care interventions on clinical outcomes, identify existing gaps in implementation, and explore future directions for improving diabetes management.

1.2 Need for Enhanced Diabetes Management

Despite the availability of numerous pharmacological agents and evolving treatment guidelines, achieving optimal glycemic control in patients with T2DM remains an ongoing challenge. Studies show that a large proportion of patients fail to meet recommended targets for glycated haemoglobin (HbA1c), blood pressure, and lipid levels, thereby increasing their risk for complications. Several interconnected factors contribute to this therapeutic gap. Firstly, patient-related barriers such as limited health literacy, poor medication adherence, and psychosocial challenges (including stress and depression) significantly hinder effective self-management. Complex medication regimens, side effects, and financial constraints can further reduce adherence. Secondly, provider-related factors, including clinical inertia (reluctance to intensify therapy despite suboptimal control) and limited time for patient counselling, impede proactive disease management. Thirdly, systemic issues such as fragmented care models and inadequate access to multidisciplinary services exacerbate these challenges, leading to reactive rather than preventive care[3].

These realities highlight the limitations of traditional physician-centred care models, which, while essential, often lack sufficient capacity to address the multifaceted nature of T2DM. Chronic care models emphasise the need for a coordinated, multidisciplinary approach that actively engages patients and integrates lifestyle counselling, education, and medication optimisation. Within this paradigm, pharmacists—traditionally focused on dispensing—have increasingly taken on expanded clinical roles, delivering structured pharmaceutical care to complement medical and nursing services[4].

1.3 Evolution and Definition of Pharmaceutical Care

The concept of pharmaceutical care emerged from a critical reevaluation of the pharmacist's role in healthcare, moving beyond product-focused dispensing toward patient-centred clinical practice. While pharmacists historically concentrated on compounding and ensuring the safe supply of medications, the latter half of the 20th century saw growing awareness of drug-related problems as significant contributors to hospitalisations and morbidity, particularly in chronic diseases like T2DM. A pivotal moment came in 1990 when Hepler and Strand formally defined pharmaceutical care as "the responsible provision of drug therapy for the purpose of achieving definite outcomes that improve a patient's quality of life". This definition marked a paradigm shift: pharmacists were no longer viewed solely as dispensers but as active members of the healthcare team, with shared

responsibility for therapeutic outcomes. Pharmaceutical care encompasses identifying, preventing, and resolving actual or potential drug-related problems; collaborating with patients and other healthcare professionals; and continuously monitoring treatment efficacy and safety[5].

Over the past three decades, pharmaceutical care has evolved into an evidence-based, structured practice integral to chronic disease management. Key services include Medication Therapy Management (MTM), which refers to a structured pharmacist-led service that involves reviewing medications, identifying drug-related problems, and optimising therapy to improve patient outcomes[6].

In the context of T2DM, the value of pharmaceutical care is particularly pronounced. Given the chronic, progressive nature of the disease and its frequent association with comorbidities and polypharmacy, pharmacist-led interventions can address critical gaps in care. Clinical studies and meta-analyses consistently demonstrate that pharmaceutical care improves HbA1c levels, enhances adherence, lowers blood pressure and lipid levels, and reduces hospital admissions. These findings support integrating pharmacists into diabetes care teams not only as medication experts but as educators, counsellors, and collaborators dedicated to improving patients' quality of life[7].

2. Pathophysiology and Clinical Challenges of Type II Diabetes Mellitus

2.1 Mechanisms Contributing to Hyperglycaemia

Type II Diabetes Mellitus (T2DM) is a complex, multifactorial metabolic disorder marked by chronic hyperglycaemia resulting from a combination of insulin resistance and progressive pancreatic β-cell dysfunction. Understanding the intricate mechanisms underlying hyperglycaemia is essential for designing targeted therapeutic strategies. A widely recognised framework to describe the disease's pathogenesis is the "ominous octet", proposed by DeFronzo, which highlights eight interrelated physiological disturbances driving hyperglycaemia in T2DM. Firstly, insulin resistance in skeletal muscle significantly reduces glucose uptake, impairing the body's ability to clear circulating glucose after meals. Concurrently, the liver exhibits inappropriate glucose production, particularly during fasting, due to hepatic insulin resistance. This overproduction contributes to elevated fasting blood glucose levels. The progressive decline of pancreatic β-cell function further exacerbates hyperglycaemia. Initially, β-cells compensate by increasing insulin secretion, but over time, chronic exposure to high glucose (glucotoxicity) and free fatty acids (lipotoxicity) leads to β-cell exhaustion and apoptosis[8].

Additionally, the pathophysiology involves increased secretion of glucagon from pancreatic α-cells, which further stimulates hepatic glucose production. The diminished incretin effect, particularly impaired secretion or function of hormones like GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide), results in inadequate insulin secretion after meals. Another contributing mechanism is enhanced renal glucose reabsorption via upregulated sodium-glucose cotransporter 2 (SGLT2) in the kidneys, which increases plasma glucose levels. Elevated lipolysis in adipose tissue releases free fatty acids, worsening insulin resistance and hepatic glucose output. Lastly, insulin resistance in the brain alters appetite regulation and energy balance, promoting weight gain and further aggravating insulin resistance (Figure 1). These defects do not occur in isolation; rather, they interact dynamically, creating a vicious cycle of metabolic dysregulation. Chronic low-grade inflammation and oxidative stress also play crucial roles in sustaining and amplifying insulin resistance and β-cell dysfunction. Together, these mechanisms establish the biochemical foundation for persistent hyperglycaemia, which drives the development of diabetes-related complications[9,10].

2.2 Microvascular and Macrovascular Complications

The prolonged exposure to elevated glucose levels in Type II Diabetes Mellitus (T2DM) T2DM leads to both microvascular and macrovascular complications, which significantly contribute to morbidity and mortality. Microvascular complications primarily affect small blood vessels, leading to conditions such as diabetic retinopathy, nephropathy, and neuropathy. Diabetic retinopathy remains the leading cause of preventable blindness among working-age adults worldwide. It results from capillary damage, increased vascular permeability, and neovascularisation, which ultimately compromise retinal structure and function. Diabetic nephropathy, characterised by albuminuria and declining glomerular filtration rate (GFR), is the most




Figure 1. Pathophysiology of Type II Diabetes Mellitus illustrating the "Ominous Octet", highlighting key mechanisms contributing to chronic hyperglycemia, including insulin resistance, β-cell dysfunction, increased hepatic glucose production, and impaired incretin response.

common cause of end-stage renal disease globally[11]. Neuropathy, another prevalent microvascular complication, affects both the peripheral and autonomic nervous systems. Peripheral neuropathy leads to sensory deficits, increasing the risk of foot ulcers and amputations, while autonomic neuropathy can affect cardiovascular, gastrointestinal, and genitourinary systems. Macrovascular complications, on the other hand, involve large vessels and are the leading causes of death in individuals with T2DM. These include coronary artery disease (CAD), which can manifest as angina or myocardial infarction; cerebrovascular disease, leading to transient ischemic attacks or strokes; and peripheral arterial disease (PAD), which increases the risk of critical limb ischemia and amputations. The interplay of dyslipidemia, hypertension, chronic inflammation, and hyperglycemia accelerates atherosclerotic plaque formation and destabilisation, driving macrovascular disease progression. Compounding the problem, many patients with T2DM also have other cardiometabolic risk factors such as obesity, hypertension, and dyslipidemia, which synergistically raise the risk of cardiovascular events. The presence of these complications dramatically increases healthcare utilisation and costs and profoundly affects patients' quality of life and life expectancy[12].

2.3 Barriers to Optimal Glycemic Control

Despite advancements in pharmacotherapy and clinical guidelines, a significant proportion of patients with T2DM fail to achieve optimal glycemic control, often reflected in HbA1c levels above recommended targets. Multiple barriers contribute to this gap, spanning patient-related, provider-related, and systemic factors. From a patient perspective, medication adherence remains a critical challenge. Factors such as complex drug regimens, fear of side effects like hypoglycemia, pill burden, and treatment fatigue can reduce adherence. Financial constraints, including high costs of newer medications and glucose monitoring tools, further exacerbate this issue, especially in low- and middle-income countries. Limited health literacy and inadequate understanding of diabetes self-management also hinder effective disease control. Provider-related barriers include clinical inertia, which refers to the reluctance to intensify therapy despite suboptimal glycemic control, often due to concerns about hypoglycemia risk, weight gain, or patient preferences[13]. Time constraints during consultations may limit opportunities for comprehensive patient counselling, lifestyle education, and shared decision-making. Systemic and structural barriers are equally important. Fragmented

healthcare systems lacking coordinated multidisciplinary care reduce opportunities for early intervention and consistent follow-up. Insufficient access to diabetes educators, nutritionists, and pharmacists can further compromise care quality. In some healthcare settings, the limited availability of evidence-based technologies like continuous glucose monitoring and decision-support tools restricts proactive disease management. Additionally, psychosocial factors such as depression, anxiety, and diabetes-related distress negatively impact patients' motivation and self-care behaviours. Cultural beliefs and stigma may also interfere with adherence to prescribed regimens and lifestyle changes. Together, these barriers highlight the complexity of managing T2DM in real-world settings. Addressing them requires a shift toward patient-centred, multidisciplinary care models that emphasise continuous education, behavioural support, proactive monitoring, and evidence-based pharmacotherapy optimisation. Pharmaceutical care, delivered by trained clinical pharmacists, has shown promise in overcoming several of these barriers by improving adherence, enhancing patient understanding, and supporting individualised therapy adjustments[14].

3. Pharmaceutical Care Interventions in T2DM

Pharmaceutical care in the management of Type II Diabetes Mellitus (T2DM) represents a patient-centred, evidence-based approach that extends beyond the traditional role of dispensing medications. Through systematic interventions, pharmacists help optimise therapeutic outcomes, enhance patient engagement, and bridge gaps in multidisciplinary care. Among the key interventions are Medication Therapy Management (MTM), patient counselling and education, continuous monitoring and follow-up, and collaborative practice with other healthcare professionals. Each of these plays a unique and complementary role in achieving better glycemic control and reducing the burden of diabetes complications[15]. Despite the availability of effective pharmacological therapies, achieving optimal glycemic control in T2DM remains a significant challenge. A large proportion of patients fail to meet recommended targets for HbA1c, blood pressure, and lipid levels, increasing the risk of complications. These challenges arise from a combination of patient-related, provider-related, and systemic factors.

Patient-related barriers include poor medication adherence, limited health literacy, and psychosocial factors such as stress and depression. Complex treatment regimens, fear of side effects, and financial constraints further reduce adherence and self-management.

Provider-related barriers include clinical inertia, where treatment is not intensified despite poor glycemic control, and limited consultation time for patient education and counselling.

Systemic barriers involve fragmented healthcare systems, a lack of multidisciplinary coordination, and limited access to diabetes education and monitoring tools.

Together, these factors highlight the need for integrated, patient-centred care models in which pharmaceutical care can play a significant role in improving outcomes.

3.1 Medication Therapy Management (MTM)

Medication Therapy Management (MTM) is at the core of pharmaceutical care in diabetes and is designed to ensure that every medication taken by a patient is appropriate, effective, safe, and used correctly. In patients with T2DM—who often face polypharmacy due to comorbid conditions like hypertension and dyslipidemia—MTM helps to identify and resolve drug therapy problems such as therapeutic duplications, drug-drug interactions, and inappropriate dosing, especially in the context of changing renal or hepatic function[16]. During MTM, pharmacists systematically review each patient's complete medication list, laboratory data, and clinical history to assess therapeutic effectiveness and safety. They work closely with prescribers to adjust regimens, recommend alternative therapies, and simplify complex regimens to improve adherence. MTM also supports rational use of newer agents, such as SGLT2 inhibitors and GLP-1 receptor agonists, by evaluating suitability based on cardiovascular risk profiles, weight concerns, and tolerability. Evidence supports the effectiveness of MTM in diabetes management. Studies and meta-analyses have shown significant reductions in HbA1c, improvements in blood pressure and lipid profiles, and reductions in emergency visits and hospital admissions following pharmacist-led MTM interventions. By addressing individual patient needs and treatment goals, MTM ensures that pharmacotherapy is continually optimised to align with evolving clinical evidence and patient preferences[17].

3.2 Patient Counselling and Education

Effective management of T2DM relies heavily on patients' understanding of their disease and active engagement in self-care. Pharmacist-delivered patient counselling and education are critical to building this foundation. Education sessions often include information on disease pathophysiology, treatment rationale, medication use, lifestyle modifications, and self-monitoring techniques. Practical aspects of counselling may involve demonstrating correct insulin injection techniques, explaining the timing of oral agents relative to meals, and teaching patients how to recognise and manage hypoglycemia. Pharmacists also educate patients on the importance of adherence and explain how missed doses or improper use can compromise therapeutic goals. Beyond providing information, pharmacists use motivational interviewing techniques to assess and enhance patients' readiness to change, address misconceptions, and identify barriers to adherence. Studies have shown that pharmacist-led education increases medication adherence, improves patients' confidence in managing diabetes, and leads to measurable improvements in clinical outcomes such as lower HbA1c levels and fewer acute complications[18]. Pharmacists often apply motivational interviewing techniques to enhance patient engagement. These include open-ended questioning (e.g., 'What challenges do you face in taking your medication regularly?'), reflective listening, affirmations to build confidence, and goal-setting strategies to encourage gradual behaviour change. Such approaches help address patient-specific barriers and improve adherence.

3.3 Monitoring and Follow-up

T2DM is a dynamic condition influenced by lifestyle, disease progression, and comorbidities, making continuous monitoring essential. Pharmacists play a vital role in this process by regularly assessing glycemic indices (such as fasting blood glucose and HbA1c), blood pressure, lipid levels, renal function, and signs of adverse drug reactions. Follow-up visits or calls provide opportunities to evaluate the effectiveness of therapy, assess adherence, reinforce lifestyle recommendations, and promptly identify new drug-related problems. Pharmacists may also review glucose logs and adjust therapeutic plans in collaboration with prescribers when targets are unmet. This structured follow-up helps reduce clinical inertia and ensures timely intervention. Studies have shown that pharmacist-led follow-up programs can lead to significant reductions in HbA1c, sometimes by as much as 1–2%, and reduce hospital readmissions by proactively addressing medication issues and supporting patient self-management[19].

3.4 Collaborative Practice with Healthcare Teams

Optimal diabetes management requires the integration of various healthcare professionals—including physicians, nurses, dietitians, and pharmacists—each contributing their expertise to deliver holistic care. Collaborative practice empowers pharmacists to actively participate in therapeutic decision-making, enhancing care quality and responsiveness. Through collaborative practice agreements (CPAs), pharmacists may have the authority to initiate, adjust, or discontinue therapy based on patient-specific protocols and clinical targets. This model has been associated with faster achievement of glycemic goals and improved patient satisfaction. Pharmacists in multidisciplinary teams also enhance communication among providers, prevent duplication of services, and ensure that patient care remains coordinated and patient-centred. Regular case discussions, shared electronic medical records, and interdisciplinary meetings facilitate these collaborations, supporting individualised care plans tailored to patient needs and preferences (Table 1)[20]. The American Diabetes Association and numerous international guidelines endorse pharmacist participation in diabetes care teams as an effective strategy to improve clinical and humanistic outcomes. Collaborative practice not only benefits patients but also alleviates the workload on other providers, contributing to more efficient use of healthcare resources.

4. Lifestyle and Drug Optimisation Strategies

Effective management of Type II Diabetes Mellitus (T2DM) requires more than pharmacological interventions alone; it necessitates a holistic approach that addresses lifestyle behaviours, optimises pharmacotherapy, and ensures ongoing monitoring for drug safety. Pharmaceutical care contributes significantly to these aspects by integrating patient-centred lifestyle counselling, systematic medication reviews, adherence support, and proactive pharmacovigilance. Together, these strategies enhance

Table 1. Key Pharmaceutical Care Interventions in Type II Diabetes Mellitus (T2DM)

Intervention	Main Focus	Key Benefits	Reference
Medication Therapy Management (MTM)	Review and optimise medications	↓ HbA1c, fewer drug-related problems	[21]
Patient counselling and education	Teach disease and medication self-management	↑ Adherence, ↑ patient empowerment	[22]
Monitoring and follow-up	Regular checks of HbA1c, BP, lipids, and ADRs	Sustained glycemic control, early detection	[23]
Collaborative practice	Work with physicians and care teams	Faster treatment adjustments, coordinated care	[24]

therapeutic effectiveness, reduce complications, and promote long-term patient engagement[25].

4.1 Lifestyle Modification Interventions

Lifestyle modification is the cornerstone of T2DM prevention and management, often producing benefits comparable to pharmacotherapy when properly implemented. Pharmacists play an important role in supporting lifestyle changes by providing structured counselling, education, and motivational support tailored to individual patient needs and cultural contexts. Dietary interventions focus on balanced nutrition, portion control, reduced intake of refined carbohydrates and saturated fats, and awareness of the glycaemic index of foods. Pharmacists can educate patients on reading food labels, meal planning, and practical strategies for healthier eating, which directly contribute to better glycaemic control and weight management[26]. In addition to dietary counselling, promoting regular physical activity is essential. Pharmacists encourage patients to engage in moderate aerobic exercise (e.g., brisk walking for at least 150 minutes per week) combined with resistance training. They also address common barriers to exercise, such as time constraints, mobility issues, or fear of hypoglycemia[27]. Pharmacist-led lifestyle interventions often incorporate smoking cessation counselling, alcohol moderation advice, and stress management strategies. Evidence from clinical studies indicates that these programs can reduce HbA1c by up to 1–2%, lower body mass index (BMI), and improve lipid profiles, highlighting the powerful role of pharmacists in lifestyle-based diabetes care[28].

4.2 Drug Optimisation and Adherence Enhancement

Polypharmacy is common in T2DM due to comorbid conditions such as hypertension and dyslipidaemia. Pharmacists help optimise drug therapy by selecting the most appropriate agents based on clinical guidelines, patient comorbidities, renal and hepatic function, and risk of adverse effects. Drug optimisation may include simplifying complex regimens to reduce pill burden, switching to safer or more cost-effective alternatives, and tailoring dosages to achieve therapeutic targets while minimising side effects. Adherence enhancement is equally critical, as non-adherence is a leading cause of poor glycemic control and increased risk of complications. Pharmacists employ a variety of strategies to improve adherence: Providing clear explanations of medication purposes and schedules Using pill organisers, blister packs, or mobile app reminders Synchronising medication refills to reduce pharmacy visits Addressing cost concerns by recommending generic alternatives or patient assistance programs[29]. By routinely assessing adherence through direct questioning and validated tools, pharmacists identify patients at risk of non-adherence and intervene early. Clinical evidence suggests pharmacist-led adherence programs can improve adherence rates by 20–30%, resulting in better metabolic control and fewer diabetes-related hospitalisations[30].

4.3 Pharmacovigilance and ADR Monitoring

Given the chronic nature of T2DM and frequent polypharmacy, patients are at increased risk for adverse drug reactions (ADRs) and drug-drug interactions. Pharmacists are uniquely positioned to lead pharmacovigilance efforts in outpatient and hospital settings. Pharmacists monitor for common ADRs in diabetes therapy, including hypoglycemia (especially with insulin or sulfonylureas), gastrointestinal side effects from metformin or GLP-1 receptor agonists, oedema from

thiazolidinediones, and genitourinary infections from SGLT2 inhibitors. Early identification and management of these events help prevent treatment discontinuation and complications. Additionally, pharmacists actively review patient medication lists for potential interactions—such as between antihyperglycemic agents and cardiovascular drugs—and adjust therapy in collaboration with prescribers. They educate patients on recognising signs of ADRs and encourage prompt reporting[31]. Pharmacists also document and report suspected ADRs to national pharmacovigilance programs, contributing to broader drug safety monitoring efforts. Studies have demonstrated that pharmacist-led ADR monitoring reduces the incidence of severe ADRs, improves patient safety, and supports rational use of medications in complex patients (Table 2).

5. Technology-Enabled Pharmaceutical Care

The integration of digital technologies has transformed the landscape of pharmaceutical care, enabling more personalised, accessible, and data-driven interventions for patients with Type II Diabetes Mellitus (T2DM). Technology-enhanced tools—from mobile health apps and telepharmacy to clinical decision support systems and artificial intelligence (AI)—help pharmacists monitor patients remotely, tailor recommendations, and collaborate more effectively within healthcare teams. These innovations play a vital role in addressing barriers such as geographical distance, limited healthcare resources, and the complexity of chronic disease management[35].

5.1 Mobile Health Applications (mHealth)

Mobile health applications (mHealth) have emerged as practical tools for supporting diabetes self-management. Pharmacists use these apps to help patients track blood glucose levels, monitor medication schedules, log meals and physical activity, and receive automated reminders. Through visual dashboards and trend charts, patients gain real-time feedback, which promotes engagement and better understanding of how lifestyle choices affect glycemic control. Pharmacists also recommend evidence-based apps that integrate with Bluetooth-enabled devices like glucometers or fitness trackers, enabling seamless data capture. During follow-up visits or teleconsultations, pharmacists review this data to adjust medication regimens, reinforce lifestyle advice, and address patient concerns. Clinical studies have shown that use of mHealth apps can reduce HbA1c by approximately 0.5–0.8%, enhance medication adherence, and improve patient confidence in disease management[36].

5.2 Telepharmacy Services

Telepharmacy uses telecommunications technology to deliver pharmacist-led services remotely, which is especially valuable in rural or underserved areas where access to diabetes specialists may be limited. Through video consultations, phone calls, or secure messaging platforms, pharmacists can provide medication reviews, adherence counselling, lifestyle education, and monitor therapy outcomes without requiring patients to travel. The COVID-19 pandemic accelerated the adoption of telepharmacy, demonstrating its feasibility and acceptance among patients. Studies have shown that pharmacist-led telepharmacy interventions achieve comparable outcomes to in-person care, including significant reductions in HbA1c and improved adherence rates. Additionally, telepharmacy reduces travel costs and increases the frequency of pharmacist–patient interactions, which can support ongoing behaviour change and timely therapy adjustments[37].

Table 2. Pharmaceutical care strategies in lifestyle and drug optimisation for T2DM

Strategy	Key Activities	Clinical Benefits	Reference
Lifestyle modification interventions	Diet counselling, physical activity promotion, smoking cessation, and alcohol moderation	↓ HbA1c, ↓ BMI, improved lipid profiles	[32]
Drug optimization and adherence enhancement	Medication review, regimen simplification, refill synchronisation, cost management, patient education	↑ Adherence (by 20–30%), ↓ hospitalisations, and better metabolic control	[33]
Pharmacovigilance and ADR monitoring	Monitor for ADRs, identify drug-drug interactions, educate patients, and report ADRs to national systems	Early detection of ADRs, improved safety, and reduced therapy discontinuation	[34]

5.3 Clinical Decision Support Systems (CDSS) and EMRs

Clinical decision support systems (CDSS) are digital tools integrated into electronic medical records (EMRs) that analyse patient data and provide pharmacists with evidence-based alerts and recommendations. These systems flag potential drug-drug interactions, dose adjustments for renal impairment, or suggest therapy changes based on guideline updates. By using EMRs, pharmacists can access comprehensive patient histories, laboratory results, and previous interventions, which enhance the accuracy and efficiency of medication reviews. EMRs also support better communication between pharmacists and other providers, enabling coordinated care plans and reducing duplication of services[38]. Research shows that CDSS integration into pharmacy practice improves medication safety, reduces prescribing errors, and supports more timely therapeutic interventions, ultimately contributing to improved clinical outcomes in patients with T2DM.

5.4 Remote Monitoring and AI Integration

Emerging technologies like continuous glucose monitors (CGMs), Bluetooth-enabled blood pressure cuffs, and smart pillboxes have expanded the scope of remote patient monitoring. Pharmacists can access real-time data dashboards, which enable proactive identification of trends such as frequent hypoglycemia or sustained hyperglycemia. Artificial intelligence (AI) tools further enhance this process by analysing large datasets to identify at-risk patients, predict complications, and suggest personalised interventions. AI-driven algorithms can also segment patients based on adherence patterns, helping pharmacists prioritise high-risk individuals for follow-up. For example, predictive analytics can alert pharmacists to patients likely to miss doses or those with rising HbA1c levels, prompting timely outreach. AI-based chatbots can also engage patients between visits, answering routine questions and sending automated reminders[39]. These technologies collectively empower pharmacists to deliver more targeted, efficient, and patient-centred care. By combining human clinical expertise with data-driven insights, technology-enabled pharmaceutical care has the potential to significantly improve glycemic outcomes, reduce hospitalisations, and enhance patient satisfaction (Table 3).

6. Evidence from Interventional Studies

The clinical and economic value of pharmaceutical care in Type II Diabetes Mellitus (T2DM) has been extensively investigated through interventional studies and systematic reviews worldwide. These studies consistently demonstrate that pharmacist-led interventions improve glycemic outcomes, medication adherence, patient quality of life, and reduce diabetes-related complications

Table 3. Technology-enabled pharmaceutical care in Type II Diabetes Mellitus (T2DM)

Tool/Intervention	Key Functions and Activities	Clinical/Practical Benefits	Reference
Mobile health applications (mHealth)	– Patient self-tracking of blood glucose, BP, diet, and activity – Automated medication reminders – Visual dashboards and trend analysis – Data sharing with pharmacists during reviews	↑ Engagement and self-efficacy ↓ HbA1c by ~0.5–0.8% Better adherence and understanding of disease dynamics	[40]
Telepharmacy services	– Remote counselling via video/phone – Medication reviews and MTM – Lifestyle and adherence support – Follow-up without in-person visits	Comparable outcomes to face-to-face care ↓ HbA1c and improved adherence Reduced travel/time burden	[41]
Clinical decision support systems (CDSS) and EMRs	– Automated alerts for drug interactions or dose adjustments – Access to labs, clinical notes, and history – Integrated documentation and care plans	↑ Medication safety and guideline adherence ↓ Errors and duplication Better coordination with care teams	[42]
Remote monitoring and AI integration	– Continuous glucose monitors (CGMs) and smart devices – Real-time dashboards for pharmacists – AI-based risk prediction and patient segmentation – Chatbots for reminders	Early detection of issues Personalized interventions ↓ Hospitalisations and improved glycemic outcomes	[43]

and healthcare utilisation. Such evidence forms a compelling rationale for integrating pharmacists into multidisciplinary diabetes care teams[44].

6.1 Global Interventional Studies and Key Outcomes

Numerous interventional studies from diverse healthcare settings illustrate the impact of pharmacist involvement in diabetes care. For instance, the IMPACT study conducted in community pharmacies in the United States reported a mean HbA1c reduction of approximately 1.8% among participating patients. This improvement was attributed to pharmacist-led medication reviews, patient counselling, and follow-up monitoring[45].

In Malaysia, the Diabetes Medication Therapy Adherence Clinic (DMTAC) model, where pharmacists provided structured education, adherence support, and therapy optimisation, resulted in HbA1c reductions ranging from 0.8% to 1.2% over six months. Similarly, the RxING study in Canada highlighted the effect of pharmacist prescribing and lifestyle counselling, achieving a mean HbA1c reduction of 1.8% along with improvements in cardiovascular risk factors[46]. Australian programs like the Diabetes Medication Assistance Service (DMAS) showed significant improvements in patients' glycemic control and self-management behaviour, while studies from Qatar, Saudi Arabia, and European countries confirmed the role of pharmacist interventions in lowering HbA1c, blood pressure, and improving patient satisfaction. A 2020 meta-analysis by Santschi *et al*., which reviewed over 30 randomised controlled trials, reported a weighted mean HbA1c reduction of approximately 0.85% attributed to pharmacist interventions, underscoring the generalisability of these findings across healthcare systems[47].

6.2 Impact on HbA1c, Adherence, Quality of Life, and Complications

Pharmacist-led interventions have consistently shown measurable improvements in key clinical and patient-centred outcomes. Reductions in HbA1c of 0.5–2.0% are frequently reported, reflecting better glycemic control and reduced risk of microvascular and macrovascular complications. Improved medication adherence, often enhanced by pharmacist counselling, regimen simplification, and reminder tools, has been documented to increase by approximately 20–30%. Beyond laboratory measures, pharmacist interventions positively influence patient quality of life (QoL). Tools such as the Diabetes Quality of Life (DQOL) questionnaire and the Morisky Medication Adherence Scale (MMAS-8) have demonstrated improvements in self-care confidence, emotional well-being, and satisfaction with treatment[48]. These interventions also contribute to a reduction in diabetes-related complications. By ensuring appropriate therapy, preventing adverse drug reactions, and supporting lifestyle changes, pharmacists help lower the incidence of hypoglycemia, delay progression of nephropathy and retinopathy, and reduce cardiovascular events. Several cohort studies and randomised trials have also reported reductions in diabetes-related hospital admissions and emergency visits by 23–30%, emphasising the preventive role of pharmaceutical care[49].

6.3 Economic Benefits of Pharmacist-led Care

The economic impact of pharmacist-led interventions is significant, driven by reduced complication rates, fewer hospitalisations, and optimised medication use. Programs such as the Asheville Project in the USA demonstrated substantial cost savings alongside clinical improvements. Participants not only experienced better glycemic control but also showed reduced absenteeism from work and lower overall healthcare expenditures[50]. In Iran, a study by Farsaei *et al*., found that pharmaceutical care reduced the frequency of diabetes complications, leading to decreased direct medical costs and improved patient-reported outcomes. Similarly, U.S. models of collaborative care involving pharmacists have been shown to lower emergency department visits and hospital stays, directly translating into financial savings for both patients and healthcare systems[51]. Moreover, pharmacist interventions often improve cost-effectiveness by promoting the use of guideline-recommended therapies, deprescribing unnecessary medications, and addressing barriers to adherence, such as high out-of-pocket costs. Economic models suggest that even modest improvements in HbA1c, when scaled across patient populations, can lead to substantial long-term savings by preventing costly complications[52]. Collectively, global evidence supports pharmacist-led pharmaceutical care as both clinically effective and economically sustainable. These findings reinforce calls from international bodies, including the American Diabetes Association and the International

Pharmaceutical Federation, to expand pharmacists' roles in chronic disease management to improve patient outcomes and healthcare efficiency.

7. Barriers to Implementation

Despite robust evidence supporting the clinical and economic benefits of pharmacist-led care in Type II Diabetes Mellitus (T2DM), widespread implementation remains limited. This is largely due to a complex set of barriers spanning systemic, patient-related, interdisciplinary, and resource domains. Understanding these challenges is crucial for designing sustainable strategies to expand pharmaceutical care within healthcare systems[53].

7.1 Healthcare System and Policy Challenges

One of the major barriers is the lack of formal recognition and reimbursement mechanisms for pharmaceutical care services in many regions. Unlike physician consultations, pharmacist-provided medication therapy management (MTM), counselling, and follow-up are often not directly reimbursed, which limits scalability and sustainability. This is particularly challenging in health systems primarily structured around fee-for-service models focused on dispensing. Fragmented healthcare delivery further hampers integration of pharmacists into care teams. Limited access to shared electronic health records (EHRs) and insufficient communication pathways restrict pharmacists' ability to make informed clinical decisions and coordinate with other providers. Regulatory constraints also pose barriers; in many countries, pharmacists cannot independently adjust therapy or order laboratory tests, reducing their potential clinical impact[54]. Finally, inconsistent national policies regarding pharmacists' scope of practice create variability in service delivery across regions. Countries that have introduced collaborative practice agreements (CPAs) or extended prescribing rights for pharmacists have shown better integration, yet such models remain underutilised globally[55].

7.2 Patient-related Barriers

Patient-level barriers significantly affect the effectiveness of pharmaceutical care interventions. Low health literacy and limited understanding of diabetes management can undermine adherence and reduce engagement in pharmacist-led services. Cultural beliefs, stigma, and language barriers can also create communication gaps, affecting the quality of counselling and patient trust. Economic factors further challenge patient participation. Costs related to medications, monitoring devices, and transportation to follow-up visits can deter ongoing engagement, particularly in low- and middle-income settings. Additionally, psychosocial factors such as depression, diabetes-related distress, and lack of motivation may reduce patients' willingness or ability to follow therapeutic recommendations and lifestyle advice. Addressing these patient-level barriers requires culturally sensitive communication, simplified educational materials, and support for psychosocial needs alongside pharmacological management[56].

7.3 Interdisciplinary Coordination Issues

Optimal diabetes care depends on collaboration among multiple healthcare professionals, including physicians, nurses, dietitians, and pharmacists. However, poor interdisciplinary coordination often limits the pharmacist's role in chronic disease management. In some healthcare settings, a lack of standardised referral pathways means that pharmacists are not consistently included in care planning. Ambiguous role definitions and limited understanding of the pharmacist's clinical contributions can lead to underutilisation of their expertise. At times, resistance from other healthcare providers—stemming from concerns about overlapping responsibilities—can create further barriers[57]. Establishing clear protocols for shared care, encouraging team meetings, and integrating pharmacists into electronic documentation systems can help overcome these challenges. Successful models show that effective collaboration enhances patient care and reduces duplication of services.

7.4 Training and Resource Limitations

Finally, the practical implementation of pharmaceutical care is constrained by training gaps and limited resources. Not all pharmacists receive comprehensive training in chronic disease management, motivational interviewing, or clinical decision-making during their education. Continuing professional development opportunities may also be limited or inaccessible, particularly in rural areas. Staffing shortages and high patient loads further restrict pharmacists' capacity to deliver individualised care. Limited infrastructure, such as a lack of private

counselling areas or insufficient digital tools, can affect the quality and consistency of interventions. Financial constraints also hinder the adoption of technologies like decision-support systems or telepharmacy platforms[58]. Addressing these limitations requires investment in workforce development, integration of clinical content into pharmacy curricula, and policy support for resource allocation. In the long term, strengthening training and infrastructure will help pharmacists effectively deliver patient-centred care, ultimately improving diabetes outcomes.

8. Models of Pharmaceutical Care Delivery

Pharmaceutical care in Type II Diabetes Mellitus (T2DM) is delivered through a range of practice models adapted to different healthcare settings, patient needs, and health system structures. While the core objectives remain the same—optimising therapy, improving adherence, and preventing complications—service delivery varies between hospital-based models, community pharmacy initiatives, and integrated collaborative programs. Understanding these models helps illustrate how pharmaceutical care can be successfully tailored and scaled[59].

8.1 Hospital-based Interventions

In hospital settings, pharmacists often play a critical role in managing complex diabetes cases, especially during acute admissions or care transitions. Hospital-based clinical pharmacy services typically focus on medication reconciliation to prevent errors, optimisation of inpatient diabetes regimens, and monitoring for adverse drug reactions (ADRs). Pharmacists participate in multidisciplinary rounds, providing real-time recommendations on insulin titration, initiation of newer antihyperglycemic agents, and adjustment of therapy for comorbid conditions such as hypertension or chronic kidney disease. They also educate patients on correct insulin administration techniques and the importance of adherence before discharge. Discharge planning is a particularly valuable pharmacist intervention, involving medication counselling, preparation of simplified regimens, and coordination of follow-up care to prevent readmissions. Evidence suggests that pharmacist-led hospital interventions can reduce medication errors by up to 30% and improve glycemic control post-discharge[60].

8.2 Community Pharmacy Initiatives

Community pharmacies serve as accessible healthcare hubs, especially for patients managing chronic conditions like T2DM. Pharmacists in community settings provide medication therapy management (MTM), adherence monitoring, and lifestyle counselling without the need for scheduled medical appointments. Common services include blood glucose screenings, blood pressure measurement, and risk assessments for complications. Pharmacists also deliver structured diabetes education programs covering diet, physical activity, and self-monitoring of blood glucose[61]. In some countries, community pharmacists operate under collaborative practice agreements (CPAs) that empower them to initiate or modify diabetes therapies based on pre-defined protocols, improving access to timely care. Studies have shown that these community-based services contribute to improving HbA1c, better medication adherence, and enhanced patient satisfaction[62]. Programs like the Australian Pharmacy Diabetes Care Program and pharmacy-based diabetes education services in the U.S. highlight the feasibility and effectiveness of pharmacist-delivered care outside hospital settings.

8.3 Case Studies and Best Practices

Several well-documented programs illustrate the success of different pharmaceutical care delivery models in real-world practice:

- **Diabetes Medication Therapy Adherence Clinic (DMTAC), Malaysia:** A pharmacist-run service providing structured follow-up, individualised counselling, and close monitoring, leading to HbA1c reductions of up to 1.2% over six months[63].
- **The Asheville Project, USA:** A community pharmacy-based model combining MTM and lifestyle coaching, resulting in better glycemic control, reduced absenteeism, and lower total healthcare costs[64].
- **Pharmacist–physician collaborative care models in Canada:** Integration of pharmacists into primary care teams, supported by shared electronic records, which enabled timely therapy adjustments and improved patient outcomes[65].

Common features of these successful models include patient-centred counselling, structured follow-up, multidisciplinary collaboration, and proactive monitoring using tools like EMRs and telepharmacy. These case studies demonstrate that while the setting and structure

may differ, the underlying principles of pharmaceutical care—personalised interventions, continuous monitoring, and interprofessional collaboration—are essential for improving diabetes outcomes[66].

9. Regulatory, Ethical, and Documentation Considerations

Effective pharmaceutical care for Type II Diabetes Mellitus (T2DM) must go beyond clinical interventions to include adherence to regulatory requirements, ethical practice, and meticulous documentation. These elements collectively ensure patient safety, promote trust, and support the delivery of high-quality, evidence-based care[67].

9.1 Guidelines and Standards

Pharmaceutical care is grounded in clinical guidelines and professional standards that define the scope and quality of practice. Internationally, organisations like the American Diabetes Association (ADA), International Diabetes Federation (IDF), and International Pharmaceutical Federation (FIP) provide frameworks for pharmacists' roles in diabetes care, including medication therapy management (MTM), patient education, and interdisciplinary collaboration[68]. In many countries, national pharmacy councils or regulatory bodies set specific standards on documentation, pharmacist–patient communication, and continuing professional development. For example, in the U.S., accreditation standards such as those from the Joint Commission of Pharmacy Practitioners (JCPP) guide MTM delivery, while in Europe, the Pharmaceutical Group of the European Union (PGEU) supports harmonised practice standards[69,70]. Adherence to these guidelines helps pharmacists deliver care that is consistent, evidence-based, and aligned with best practices, which is especially important in chronic disease management, where long-term follow-up is critical[71].

9.2 Patient Consent and Confidentiality

Patient autonomy and privacy are central to ethical pharmaceutical care. Pharmacists must obtain informed consent before initiating services like MTM, medication reviews, or participation in research. This includes explaining the purpose of interventions, potential benefits, and how patient data will be used[72]. Maintaining confidentiality is equally critical, especially when handling sensitive health data stored in electronic health records (EHRs) or shared during multidisciplinary meetings. Pharmacists must comply with legal requirements, such as the Health Insurance Portability and Accountability Act (HIPAA) in the U.S. or the General Data Protection Regulation (GDPR) in the EU, which set standards for data protection and patient privacy[73]. Clear communication about data handling practices helps build patient trust and ensures compliance with national and international privacy laws.

9.3 Ethical Principles in Chronic Disease Management

Pharmaceutical care for T2DM often involves complex decisions, such as balancing glycemic targets against the risk of hypoglycemia or deciding when to simplify therapy to improve adherence. Ethical principles—autonomy, beneficence, non-maleficence, and justice—guide pharmacists in these decisions[74].

- **Autonomy** requires respecting patients' preferences and involving them in shared decision-making[75].
- **Beneficence** and **non-maleficence** guide pharmacists to recommend interventions that maximise benefit while minimising harm, including avoiding unnecessary medications or adverse drug reactions[76].
- **Justice** ensures equitable care, especially for vulnerable populations who may face barriers due to cost, language, or geographic location[77].

Ethical practice also requires cultural sensitivity, openness to patient beliefs, and recognition of psychosocial factors affecting adherence and disease outcomes. Incorporating these ethical principles alongside regulatory standards and thorough documentation ensures that pharmaceutical care is not only clinically effective but also respectful, transparent, and patient-centred[78].

10. Future Directions and Innovations

As healthcare evolves toward more patient-centred, data-driven models, pharmaceutical care in Type II Diabetes Mellitus (T2DM) is also poised to advance beyond traditional practice. Emerging fields like pharmacogenomics, artificial intelligence (AI), and preventive care are reshaping how pharmacists deliver

individualised interventions and proactively manage disease risk. These innovations promise not only to improve clinical outcomes but also to redefine the pharmacist's role within multidisciplinary care teams[79,80].

10.1 Pharmacogenomics and Personalised Medicine

Pharmacogenomics—the study of how genetic variations affect drug response—offers significant potential to individualise diabetes therapy. Variants in genes encoding drug-metabolising enzymes (e.g., CYP2C9), drug transporters, and therapeutic targets (such as KCNJ11 in sulfonylurea response) can influence drug efficacy and risk of adverse effects[81]. In the context of T2DM, pharmacists trained in pharmacogenomics could help select the most suitable medication class, adjust dosages, and monitor for genotype-specific adverse drug reactions[82]. For instance, certain patients may benefit more from incretin-based therapies based on their genetic profile, while others may have a higher risk of metformin intolerance. Integrating pharmacogenomic data into medication therapy management (MTM) allows pharmacists to personalise regimens beyond clinical characteristics alone, increasing therapeutic success and patient safety. As testing becomes more accessible, pharmacists are likely to play a key role in interpreting results and guiding patients and prescribers toward individualised treatment strategies[83,84].

10.2 AI and Predictive Analytics

Artificial intelligence (AI) and predictive analytics represent another frontier in pharmaceutical care. By analysing large datasets—including electronic health records, real-time monitoring devices, and pharmacy refill data—AI systems can identify patterns and predict outcomes such as non-adherence, risk of hypoglycemia, or likelihood of hospitalisation[85,86]. For pharmacists, AI tools could automate routine risk stratification, flag high-risk patients for proactive follow-up, and even suggest tailored interventions based on individual patient profiles. Machine learning models might, for example, forecast rising HbA1c levels or alert pharmacists to potential drug-drug interactions before prescribing[87,88]. In addition, AI-powered chatbots and virtual assistants can provide 24/7 patient support, answer medication questions, and send reminders, supplementing pharmacists' face-to-face counselling. Early pilot studies suggest that combining AI insights with human clinical expertise enhances patient outcomes and efficiency[89,90].

10.3 Expanding Pharmacist Roles in Preventive Care

As the global burden of diabetes continues to rise, the pharmacist's role is expected to expand further into prevention and early intervention[91]. Community and hospital pharmacists are increasingly positioned to identify patients with prediabetes, metabolic syndrome, or cardiovascular risk factors and provide targeted education and lifestyle counselling. Pharmacist-led diabetes prevention programs—similar to those piloted in the U.S. National Diabetes Prevention Program (DPP)—can help delay or prevent the onset of T2DM through structured coaching on weight management, physical activity, and diet[92,93]. Moreover, pharmacists could contribute to public health initiatives, conduct risk assessments in underserved populations, and lead workplace or community wellness programs[94]. These preventive roles align with broader healthcare goals of shifting from reactive treatment to proactive risk reduction. Together, pharmacogenomics, AI, and preventive care reflect a future in which pharmacists are central to personalised, data-driven, and community-based approaches to diabetes management. Embracing these innovations will help ensure pharmaceutical care remains relevant, effective, and patient-centred in the decades ahead[95].

11. Conclusion

Pharmaceutical care plays a critical role in improving the management of Type II Diabetes Mellitus by addressing key challenges such as poor adherence, suboptimal glycemic control, and medication-related problems. Evidence from global interventional studies confirms that pharmacist-led interventions significantly reduce HbA1c levels (by approximately 0.5–2%), enhance medication adherence, improve patient quality of life, and lower the incidence of diabetes-related complications and hospitalisations. In addition to clinical benefits, pharmaceutical care contributes to economic efficiency by reducing healthcare utilisation and optimising medication use. However, barriers such as limited policy support, inadequate reimbursement mechanisms, and a lack of interdisciplinary collaboration continue to hinder

its widespread implementation. Future advancements, including pharmacogenomics, artificial intelligence, and digital health tools, are expected to further enhance the scope and effectiveness of pharmaceutical care. Overall, integrating pharmacists into multidisciplinary healthcare teams represents a practical and scalable strategy to improve long-term outcomes and reduce the global burden of T2DM.

12. Acknowledgements

The author sincerely thanks Bhaskar Medical College, Bhaskar Pharmacy College and research guide Dr R. Gandhimathi for supporting the work.

13. References

1. Vivian EM. Effects of pharmacist outpatient interventions on adults with diabetes mellitus: a systematic review. Pharmacotherapy. 2008; 28(4):421–436. https://doi.org/10.1592/phco.28.4.421 PMid: 18363526.
2. AlMazrou SH. International Diabetes Federation. IDF Diabetes Atlas, 10th edition. Brussels, Belgium: 2021.
3. American Diabetes Association. Standards of medical care in diabetes—2024. Diabetes Care. 2024; 47(Suppl 1):S1–S190.
4. DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009; 58(4):773–795. https://doi.org/10.2337/db09-9028 PMid: 19336687 PMCid: PMC2661582.
5. Garber AJ, Handelsman Y, Grunberger G, *et al.* Consensus statement by the AACE and ACE on comprehensive T2DM management. Endocr Pract. 2020; 26(1):107–139. https://doi.org/10.4158/CS-2019-0472 PMid: 32022600.
6. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990; 47(3):533–543. https://doi.org/10.1093/ajhp/47.3.533 PMCid: PMC13246115.
7. Santschi V, Chiolero A, Burnand B, Colosimo AL, Paradis G. Impact of pharmacist care in the management of cardiovascular disease risk factors: a systematic review and meta-analysis. Arch Intern Med. 2011; 171(16):1441–1453. https://doi.org/10.1001/archinternmed.2011.399 PMid: 21911628.
8. Machado M, Bajcar J, Guzzo GC, Einarson TR. Effect of pharmacist intervention on glycemic control in diabetes: a systematic review and meta-analysis. Diabet Med. 2007; 24(12):1373–1381.
9. Wubben DP, AlShathri AA, AlRumaih AH, *et al.* Impact of pharmacist interventions on clinical outcomes in type 2 diabetes: systematic review and meta-analysis. Saudi Pharm J. 2021; 29(10):1090–1100.
10. Okemah J, Peng J, Quinones M. Addressing clinical inertia in type 2 diabetes mellitus: a review. Adv Ther. 2018; 35(11):1735–1745. https://doi.org/10.1007/s12325-018-0819-5 PMid: 30374807 PMCid: PMC6223992.
11. Chisholm-Burns MA, Kim Lee J, Spivey CA, Slack M, Herrier RN, Hall-Lipsy E, *et al.* US pharmacists' effect as team members on patient care: systematic review and meta-analyses. Med Care. 2010; 48(10):923–933. https://doi.org/10.1097/MLR.0b013e3181e57962 PMid: 20720510.
12. Cranor CW, Bunting BA, Christensen DB. The Asheville Project. J Am Pharm Assoc. 2003; 43(2):173–184. https://doi.org/10.1331/108658003321480713 PMid: 12688435 PMCid: PMC13246115.
13. Blenkinsopp A, Bond C, Raynor DK. Medication reviews. Br J Clin Pharmacol. 2012; 74(4):573–580. https://doi.org/10.1111/j.1365-2125.2012.04331.x PMid: 22607195 PMCid: PMC3477324.
14. Farsaei S, Sabzghabaee AM, Zargarzadeh AH, Amini M. Effect of pharmaceutical care on clinical outcomes of T2DM patients. J Res Med Sci. 2011; 16(4):532–539.
15. Odegard PS, Gray SL. Barriers to medication adherence in poorly controlled diabetes. Diabetes Educ. 2008; 34(4):692–697. https://doi.org/10.1177/0145721708320558 PMid: 18669811.
16. American Association of Diabetes Care and Education Specialists (ADCES). ADCES7 self-care behaviors. Diabetes Educ. 2020; 46(2):139–153. https://doi.org/10.1177/0145721719894903 PMid: 31928334.
17. Vasilenko MA, Kosova IP, Anokhina MV. Role of pharmacists in patient counseling in T2DM. Res Social Adm Pharm. 2022; 18(3):2146–2154.
18. Bukhsh A, Khan TM, Lee SWH, Lee LH, Chan KG, Goh BH. Efficacy of pharmacist-led educational interventions on diabetes management: systematic review and meta-analysis. Front Pharmacol. 2018; 9:339. https://doi.org/10.3389/fphar.2018.00339 PMid: 29692730 PMCid: PMC5902757.
19. Alhabib S, Aldraimly M, Alfarhan A. Pharmacist intervention in diabetes management: a review. Saudi Pharm J. 2016; 24(5):641–648. https://doi.org/10.1016/j.jsps.2014.07.008 PMid: 27330374 PMCid: PMC4908050.
20. FIP. Pharmacists in diabetes care: global report. International Pharmaceutical Federation. 2021.
21. Taveira TH, Dooley AG, Cohen LB, Khatana SA, Wu WC. Pharmacist-led group medical appointment model in diabetes care: a randomized controlled trial. Diabetes Educ. 2014; 40(3):344–355.
22. Bunting BA, Smith BH, Sutherland SE. The Asheville Project: clinical and economic outcomes of a community-based long-term medication therapy management

program. J Am Pharm Assoc. 2008; 48(1):23–31. https://doi.org/10.1331/JAPhA.2008.07140 PMid: 18192127.
23. Carter BL, Ardery G, Dawson JD, *et al*. Physician and pharmacist collaboration to improve BP control. Arch Intern Med. 2009; 169(21):1996–2002. https://doi.org/10.1001/archinternmed.2009.358 PMid: 19933962 PMCid: PMC2882170.
24. Tan EC, Stewart K, Elliott RA, George J. Pharmacist services in home care for T2DM: systematic review. Res Social Adm Pharm. 2014; 10(1):228–247.
25. Blalock SJ, Roberts AW, Lauffenburger JC, Thompson T, O'Connor SK. The effect of patient–pharmacist interactions on medication adherence. Res Social Adm Pharm. 2013; 9(6):817–827.
26. Garcia-Perez LE, Alvarez M, Dilla T, Gil-Guillén V, Orozco-Beltrán D. Adherence to therapies in diabetes. Patient Prefer Adherence. 2013; 7:863–871.
27. Polinski JM, Moore JM, Shrank WH, *et al*. Barriers to pharmacy-based chronic disease management. J Am Pharm Assoc. 2010; 50(1):67–71.
28. Salvo MC, Cannon-Breland ML. Pharmacist provision of primary care in patient-centered medical homes. Am J Health Syst Pharm. 2015; 72(6):466–471.
29. Zillich AJ, McDonough RP, Carter BL, Doucette WR. Influential factors for pharmacist participation in MTM. J Am Pharm Assoc. 2004; 44(3):330–336.
30. Sabaté E. Adherence to long-term therapies: evidence for action. WHO. 2003.
31. Berenguer B, La Casa C, de la Matta MJ, Martín-Calero MJ. Pharmaceutical care: past, present and future. Curr Pharm Des. 2004; 10(31):3931–3946. https://doi.org/10.2174/1381612043382521 PMid: 15579081.
32. Strand LM, Cipolle RJ, Morley PC. Pharmaceutical care practice: the patient-centered approach. McGraw Hill; 2012.
33. van Eikenhorst L, Salema NE, Anderson C, *et al*. Interprofessional collaboration in diabetes care. Int J Clin Pharm. 2017; 39(3):412–419.
34. Al-Qazaz HK, Sulaiman SA, Hassali MA, Shafie AA, Sundram S. Diabetes knowledge and practice among patients. Patient Prefer Adherence. 2011; 5:503–511.
35. Tsuyuki RT, Rosenthal MM, Pearson GJ. The RxING study: pharmacist prescribing and glycemic control. Diabetes Care. 2016; 39(6):953–959.
36. Al Hamarneh YN, Rosenthal MM, Tsuyuki RT. Pharmacist intervention in T2DM: systematic review and meta-analysis. Diabetes Obes Metab. 2013; 15(10):913–922.
37. Marcy TR, Britton ML, Harrison D. Identification of drug-related problems. Ann Pharmacother. 2005; 39(12):2024–2029. https://doi.org/10.1345/aph.1E564 PMid: 15728327.
38. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence. Circulation. 2009; 119(23):3028–3035. https://doi.org/10.1161/CIRCULATIONAHA.108.768986 PMid: 19528344.
39. Tran JN, Yang E, Fisher M, *et al*. Impact of adherence on diabetes outcomes. Am J Manag Care. 2021; 27(5):e142–e149.
40. Pousinho S, Morgado M, Falcão A, Alves G. Pharmacist interventions in T2DM: meta-analysis. J Manag Care Spec Pharm. 2016; 22(6):621–635. https://doi.org/10.18553/jmcp.2016.22.5.493 PMid: 27123912 PMCid: PMC10397609.
41. Holdford DA, Patel NC, Edlund BJ. Pharmacist interventions and HbA1c outcomes: systematic review. Ann Pharmacother. 2015; 49(1):77–89.
42. Sookaneknun P, Saramunee K, Rittiluechai K, *et al*. Effect of pharmacist intervention on diabetes control in Thailand. Int J Clin Pharm. 2017; 39(2):394–402. https://doi.org/10.1007/s11096-017-0435-5 PMid: 28285390.
43. Al-Taweel D, Awad A, Al-Omar B. Impact of clinical pharmacist interventions on diabetes outcomes. Saudi Pharm J. 2020; 28(12):1720–1726.
44. Lee JK, Grace KA, Taylor AJ. Effect of pharmacist interventions on adults with diabetes: a meta-analysis. J Am Coll Clin Pharm. 2006; 45(9):1339–1346.
45. American Pharmacists Association, National Association of Chain Drug Stores Foundation. Medication therapy management in pharmacy practice: core elements. J Am Pharm Assoc. 2008; 48(3):341–353. https://doi.org/10.1331/JAPhA.2008.08514 PMid: 18595820.
46. International Pharmaceutical Federation (FIP). FIP Development Goals. 2021.
47. Farley JF, Cline RR, Schommer JC, Hadsall RS. Medication therapy management services: new practice opportunities. J Am Pharm Assoc. 2008; 48(1):26–35.
48. Lin K, Park C, Li M, Wang X, Li X, Li W. Pharmacist-led interventions to improve medication adherence in diabetes: meta-analysis. Patient Educ Couns. 2020; 103(12):2631–2640.
49. Chisholm-Burns MA, Spivey CA. Pharmacist intervention on medication adherence and quality of life. Patient Prefer Adherence. 2012; 6:155–162.
50. National Institute for Health and Care Excellence (NICE). Type 2 diabetes in adults: management. NICE guideline [NG28]; 2015.
51. Marcolino MS, Maia JX, Alkmim MB, Boersma E, Ribeiro AL. Telemedicine to improve diabetes care: systematic review. J Med Internet Res. 2013; 15(11):e228.
52. Omboni S, Caserini M, Coronetti C. Telemedicine in diabetes management: a systematic review. Diabetes Ther. 2020; 11(6):1199–1210.
53. Traynor K. Pharmacists using telehealth to manage diabetes. Am J Health Syst Pharm. 2020; 77(13):1002–1005. https://doi.org/10.1093/ajhp/zxaa140 PMid: 32548609.

54. Lee T, Kuo GM, Tran H, *et al*. Mobile health applications in diabetes: review of evidence. JMIR Mhealth Uhealth. 2021; 9(5):e23477. https://doi.org/10.2196/23477 PMid: 33587045 PMCid: PMC7920757.
55. Ramadas A, Chan CKY, Oldenburg B, Hussein Z, Quek KF. mHealth apps in diabetes self-management: systematic review. JMIR Mhealth Uhealth. 2018;6(3):e10776.
56. Sutton RT, Pincock D, Baumgart DC, Sadowski DC, Fedorak RN, Kroeker KI. Artificial intelligence in medicine. J Intern Med. 2020; 288(1):62–81.
57. Contreras I, Vehi J. Artificial intelligence for diabetes management and decision support. Diabetes Metab Res Rev. 2018; 34(4):e2983. https://doi.org/10.2196/preprints.10775
58. Nittas V, Lun P, Ehrler F, Puhan MA. mHealth adoption in diabetes: scoping review. PLoS One. 2019; 14(6):e0219149.
59. Kelley M, Lee B, Wilcox L. AI-based chatbots for diabetes education: pilot study. JMIR Form Res. 2022; 6(7):e36129.
60. Cutler RL, Fernandez-Llimos F, Frommer M, Benrimoj C, Garcia-Cardenas V. Economic impact of pharmacist interventions: systematic review. Res Social Adm Pharm. 2018; 14(10):863–882.
61. Murad MH, Coto-Yglesias F, Wang AT, Sheidaee N, Mullan RJ, Elamin MB, Erwin PJ, Montori VM. Clinical effectiveness of pharmacist services in diabetes. Ann Pharmacother. 2012; 46(12):1707–1716.
62. Rychert M, Shaw J, Sheridan J. Policy barriers to pharmacy-based diabetes care. Health Policy. 2018; 122(3):256–262. https://doi.org/10.1016/j.healthpol.2017.10.007 PMid: 29113728.
63. Jager AJ, Wynia MK. Who gets a pharmacist-provided MTM? Am J Health Syst Pharm. 2012; 69(2):128–135.
64. Puspitasari HP, Aslani P, Krass I. Barriers to delivering pharmacy services in diabetes care. Res Social Adm Pharm. 2009; 5(4):275–284.
65. Dobson RT, Taylor JG, Henry CJ, Taylor DA, Francis PA, Bowe SJ. Barriers to pharmacist participation in diabetes care. Int J Pharm Pract. 2009; 17(5):259–265.
66. Alrasheedy AA, Alhassun MS, Almuqbil FA, *et al*. Barriers to pharmaceutical care in community pharmacies. Saudi Pharm J. 2021; 29(6):539–546.
67. FIP and WHO. Global Competency Framework for Pharmacy Practice. 2012.
68. Bajorek BV, Lemay KS, Magin PJ, Roberts C, Krass I, Armour CL. Pharmacist role in multidisciplinary diabetes care teams. J Pharm Pract Res. 2015; 45(1):39–46.
69. Santos P, Pereira M, Costa E, *et al*. Pharmacists and diabetes prevention: narrative review. Pharm Pract (Granada). 2019; 17(1):1397.
70. Odegard PS, Capoccia K. Medication taking and diabetes: a review. Diabetes Educ. 2007; 33(6):1014–1029. https://doi.org/10.1177/0145721707308407 PMid: 18057270 PMCid: PMC8109801.
71. Inzucchi SE, Bergenstal RM, Buse JB, *et al*. Management of hyperglycemia in type 2 diabetes. Diabetes Care. 2015; 38(1):140–149. https://doi.org/10.2337/dc14-2441 PMid: 25538310 PMCid: PMC10307744.
72. Frier BM, Schernthaner G, Heller SR. Hypoglycemia and cardiovascular outcomes. Diabetes Care. 2011; 34(Suppl 2):S132–S137. https://doi.org/10.2337/dc11-s220 PMid: 21525444 PMCid: PMC3632150.
73. Papatheodorou K, Papanas N, Banach M, Papazoglou D, Edmonds M. Complications of diabetes. Curr Vasc Pharmacol. 2018; 16(2):154–163.
74. Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors. Patient Prefer Adher. 2016; 10:1299–1307. https://doi.org/10.2147/PPA.S106821 PMid: 27524885 PMCid: PMC4966497.
75. Krass I, Schieback P, Dhippayom T. Adherence interventions by community pharmacists. Int J Clin Pharm. 2015; 37(3):475–482.
76. Maitre M, *et al*. Pharmacist-led telemedicine diabetes care: meta-analysis. J Diabetes Sci Technol. 2023; 17(2):349–359.
77. Seidling HM, Mahler C, Strauß L, *et al*. CDSS and pharmacist decision making. Int J Med Inform. 2020; 136:104099.
78. Taitel M, Jiang J, Rudkin K, Ewing S, Duncan I. Impact of pharmacist-based diabetes care. Popul Health Manag. 2012; 15(1):18–22.
79. Pereira M, Kerr M, Coombes I. Pharmacogenomics in diabetes. Pharmacotherapy. 2020; 40(6):594–606.
80. Luzum JA, Pakyz RE, Elsey AR, Haidar CE, Peterson JF. Precision medicine and pharmacists. Am J Health Syst Pharm. 2017; 74(3):165–174.
81. Fröhlich H, Balling R, Beerenwinkel N, *et al*. AI in diabetes: overview. Mol Metab. 2018; 9:57–70.
82. Hepler CD. The future of pharmaceutical care. J Pharm Care Health Syst. 2016; 3(2):e123.
83. International Diabetes Federation. Pharmacists and diabetes: global report. Brussels; 2019.
84. WHO. WHO Global Report on Diabetes. Geneva; 2016.
85. Santschi V, Chiolero A, Paradis G. Pharmacist interventions: effect on HbA1c. Diabetes Obes Metab. 2012; 14(10):885–894.
86. National Diabetes Prevention Program (US CDC). Pharmacists and diabetes prevention. 2020.
87. Alhabib S, Aldraimly M, Alfarhan A. Pharmacists in patient education. Saudi Pharm J. 2016; 24(5):641–648. https://doi.org/10.1016/j.jsps.2014.07.008 PMid: 27330374 PMCid: PMC4908050.

88. Sabater-Galindo M, *et al*. Pharmaceutical care in diabetes. J Diabetes Res. 2016; 2016:1–10.
89. Bond CA, Raehl CL. Clinical pharmacy services and hospital mortality. Pharmacotherapy. 2007; 27(4):481–493. https://doi.org/10.1592/phco.27.4.481 PMid: 17381374.
90. Stewart DC, George J, Bond CM, *et al*. Responsibility for medication review. Int J Pharm Pract. 2011; 19(5):290–302.
91. Carter BL. Evolution of pharmacist care in chronic diseases. J Am Coll Clin Pharm. 2019; 2(3):247–253.
92. McDonough RP, Doucette WR. Developing collaborative working relationships. J Am Pharm Assoc. 2001; 41(5):682–692. https://doi.org/10.1016/S1086-5802(16)31315-8
93. Bryant LJ, Coster G, Gamble GD, McCormick RN. Hospital to community pharmacy discharge: randomized trial. Br J Clin Pharmacol. 2009; 68(5):767–774.
94. Sabater-Hernández D, *et al*. Implementation of services in community pharmacies. Res Social Adm Pharm. 2016; 12(4):603–614.
95. International Pharmaceutical Federation (FIP). Vision for Pharmacy Practice 2030. 2021.

Authors Contributions

Susmitha: contributed to conceptualization and methodology, **Susmitha and Gandhimathi**: Performed the literature research, analyzed the data and drafted the manuscript, **Susmitha**: critically revised the work, All the authors have read and agreed to the published version of the manuscript

Access this journal online	
Website: https://informaticsjournals.com/journals/toxi/home	**Quick Response Code**